US 11,788,085 B2
Treating and preventing microbial infections
Morten Sommer, Copenhagen Ø (DE); Virginia Martinez, Copenhagen Ø (DK); Eric Van Der Helm, Copenhagen Ø (DE); Jakob Krause Haaber, Copenhagen Ø (DK); Ana De Santiago Torio, Copenhagen Ø (DK); Christian Grøndahl, London (GB); and Jasper Clube, London (GB)
Assigned to SNIPR Biome ApS, Copenhagen Ø (DK)
Filed by SNIPR Biome ApS, Copenhagen Ø (DE)
Filed on May 19, 2022, as Appl. No. 17/748,875.
Application 17/748,875 is a continuation of application No. 17/029,860, filed on Sep. 23, 2020, granted, now 11,485,973.
Application 17/029,860 is a continuation of application No. 16/700,856, filed on Dec. 2, 2019, granted, now 10,920,222, issued on Feb. 16, 2021.
Application 16/700,856 is a continuation of application No. 15/967,484, filed on Apr. 30, 2018, granted, now 10,760,075, issued on Sep. 1, 2020.
Prior Publication US 2022/0290133 A1, Sep. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/11 (2006.01); A61P 31/04 (2006.01); A61K 39/395 (2006.01); A61K 38/46 (2006.01); C07K 16/28 (2006.01)
CPC C12N 15/11 (2013.01) [A61K 38/465 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61P 31/04 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12N 2310/20 (2017.05); C12N 2320/30 (2013.01); C12N 2320/31 (2013.01); Y02A 50/30 (2018.01)] 28 Claims
 
1. A method of treating or reducing the risk of a urinary tract infection caused by first bacteria in a subject, the method comprising:
selectively killing the first bacteria in the subject by cutting a target site comprised by the genomes of the first bacteria using an RNA-guided Cas nuclease,
wherein the method comprises administering to the subject a nucleic acid sequence comprising or encoding one or more guide RNAs (gRNAs) at a first time (T1) and at a second time (T2), wherein T2 is at least 3 hours after T1,
wherein the one or more gRNAs hybridize to the target site to guide the Cas nuclease to cut the target site, thereby killing the first bacteria,
wherein the subject comprises second bacteria of one or more strains or species that are different from that of the first bacteria, wherein the genomes of the second bacteria do not comprise the target site, wherein the genomes of the second bacteria are not cut by the Cas nuclease in the subject, whereby second bacteria survive in the presence of the Cas nuclease in the subject, and
wherein the number of the first bacteria is reduced at least 100-fold by the first 30 minutes after exposing the subject to the one or more gRNAs.